Print

Active Biotech AB Interim report January - March 2012

2012-04-26

  • Laquinimod - submission of application for regulatory approval in the EU planned for second half of 2012
    - Phase III data presented at the Annual Meeting of the American Academy of Neurology (AAN)
  • TASQ- a Phase I investigator-sponsored clinical trial is under way
    - enrolment of patients to Phase III study proceeding according to schedule
  • ANYARA- Phase III trial continuing according to plan
  • 57-57- a clinical trial in systemic sclerosis/scleroderma in progress
  • ISI- project is proceeding as planned
  • Net sales SEK 2.6 M (2.7)
  • Operating loss SEK 100.7 M (loss: 70.9)
  • Net loss SEK 99.0 M (loss: 69.3 )
  • Loss per share for the period was SEK 1.44 (loss: 1.02)

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44


Active Biotech AB (Corp Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

This report is also available at www.activebiotech.com


pdfActive Biotech AB Interim report January - March 2012



Back